



英文版仅为中文版之翻译，若中英歧义，请以中文版为准。

The English translation is for reference purposes only.

In the event of any discrepancy between the Chinese original and the English translation,
the Chinese original shall prevail.

2023 第三季度报告

The Third Quarter Report in 2023

甘李药业股份有限公司
GAN & LEE PHARMACEUTICALS.
股票代码：603087
STOCK CODE: 603087

目 录

Contents

| | |
|--|----|
| 重要内容提示 Important Notes | 3 |
| 一、主要财务数据 I Major Financial Data | 4 |
| 二、股东信息 II Shareholder Information | 10 |
| 三、季度财务报表 III Quarterly Financial Statements | 13 |

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。

The Board of Directors and all Company directors warrant that there are no false records, misleading statements, or material omissions in this announcement. They are legally responsible for the truthfulness, accuracy, and completeness of its contents.

重要内容提示：

公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。

公司负责人甘忠如、主管会计工作负责人孙程及会计机构负责人(会计主管人员)周丽保证季度报告中财务信息的真实、准确、完整。

第三季度财务报表是否经审计

否

Important Notes:

The Board of Directors, the Supervisory Committee and the directors, supervisors and senior management of the Company guarantee the truthfulness, accuracy and completeness of the contents of the quarterly report, and that there are no false records, misleading statements or material omissions, for which they shall be individually and jointly liable.

Zhongru Gan (Legal Representative), Cheng Sun (Chief Accountant) and Li Zhou (Head of Accounting Department) hereby certify that the financial report set out in the quarterly report is true, accurate and complete.

Whether the third quarter financial statements are audited

No

主要财务数据

Major Financial Data



一、主要财务数据

I Major Financial Data

(一) 主要会计数据和财务指标

(I) Major accounting data and financial indicators

单位：元 币种：人民币
Unit: RMB

| 项目 Item | 本报告期 Current reporting period | 本报告期比上年同期增 减变动幅度(%) Change in the current reporting period over the same period of the previous year (%) | 年初至报告期末 Beginning to end of reporting period | 年初至报告期末比上年同期 增减变动幅度(%) Change from beginning to end of the current reporting period over the same period of the previous year(%) |
|---|-------------------------------------|---|---|--|
| 营业收入 Operating income | 675,905,764.02 | 68.10 | 1,905,670,877.67 | 54.07 |
| 归属于上市公司股东的净利润 Net profit attributable to shareholders of the listed company | 132,320,637.97 | 不适用 N/A | 266,475,880.66 | 不适用 N/A |
| 归属于上市公司股东的扣除非经 常性损益的净利润 Net profit attributable to shareholders of the listed company after deduction of non-recurring profits or losses | 121,920,823.86 | 不适用 N/A | 224,141,960.97 | 不适用 N/A |
| 经营活动产生的现金流量净额 Net cash flows from operating activities | 不适用 N/A | 不适用 N/A | -76,956,258.80 | -116.70 |
| 基本每股收益(元/股) Basic earnings per share (RMB per share) | 0.24 | 不适用 N/A | 0.47 | 不适用 N/A |
| 稀释每股收益(元/股) Diluted earnings per share (RMB per share) | 0.24 | 不适用 N/A | 0.47 | 不适用 N/A |
| 加权平均净资产收益率(%) Weighted average return on net assets (%) | 1.35 | 增加3.57个百分点 Increase of 3.57% | 2.73 | 增加6.91个百分点 Increase of 6.91% |

| 项目 Item | 本报告期末 End of the current reporting period | 上年度末 End of the previous year | 本报告期末比上年度末增 减变动幅度(%) Change in the current reporting period over the end of the previous year (%) |
|---|---|-------------------------------------|---|
| 总资产 Total assets | 10,825,037,574.61 | 10,606,912,380.06 | 2.06 |
| 归属于上市公司股东的所有者权益 Owners' equity attributable to shareholders of listed company | 9,890,606,224.90 | 9,585,802,149.50 | 3.18 |

注：“本报告期”指本季度初至本季度末3个月期间，下同。

Note: "Current reporting period" refers to the three-month period from beginning to end of the current quarter, the same below.

(二) 非经常性损益项目和金额

(II) Items and amounts of non-recurring gains and losses

单位：元 币种：人民币
Unit: RMB

| 项目 | Item | 本报告期金额 Amount for the current reporting period | 年初至报告期末金额 Amount from beginning to end of the current reporting period | 说明 Note |
|---|--|---|--|------------|
| 非流动性资产处置损益 | Gains and losses on disposal of non-current assets | -209.40 | -173,502.34 | |
| 计入当期损益的政府补助，但与公司正常经营业务密切相关，符合国家政策规定、按照一定标准定额或定量持续享受的政府补助除外 | Government grants recognized in profit or loss other than grants which are closely related to the Company's business and are either in fixed amounts or determined under quantitative methods in accordance with the national standard | 2,883,564.26 | 13,407,189.29 | |
| 除同公司正常经营业务相关的有效套期保值业务外，持有交易性金融资产、衍生金融资产、交易性金融负债、衍生金融负债产生的公允价值变动损益，以及处置交易性金融资产、衍生金融资产、交易性金融负债、衍生金融负债和其他债权投资取得的投资收益 | Gains or losses from changes in fair value of financial assets held for trading, derivative financial assets, financial liabilities held for trading, derivative financial liabilities, and investment gains from the disposal of financial assets held for trading, derivative financial assets, financial liabilities held for trading, derivative financial liabilities and other debt investments, except for effective hedging operations related to the Company's normal business operations | 11,326,832.38 | 42,263,419.08 | |
| 除上述各项之外的其他营业外收入和支出 | Non-operating income and expenses other than those listed above | -1,844,998.13 | -5,973,195.04 | |
| 其他符合非经常性损益定义的损益项目 | Other items of profit or loss that meet the definition of non-recurring profit or loss | 2,199.01 | 529,642.18 | |
| 减：所得税影响额 | Less: Amount affected by income tax | 1,967,574.01 | 7,719,633.48 | |
| 合计 | Total | 10,399,814.11 | 42,333,919.69 | |

(三) 主要会计数据、财务指标发生变动的情况、原因 (III) Changes in major accounting data and financial indicators, and the reasons therefor

| 项目名称 | Item | 变动比例 (%) Percentage of change (%) | 主要原因 | Main reason |
|--------------------------------|---|--------------------------------------|---|---|
| 营业收入_本报告期 | Operating income_current reporting period | 68.10 | 见表格下方说明。 | See note below the table. |
| 营业收入_年初至报告期末 | Operating income_beginning to end of the current reporting period | 54.07 | 见表格下方说明。 | See note below the table. |
| 归属于上市公司股东的净利润_本报告期 | Net profit attributable to shareholders of listed companies_current reporting period | 不适用 N/A | 与上年同期相比, 实现扭亏为盈, 主要系本报告期营业收入增长、销售费用减少所致。 | Compared with the same period of the previous year, a turnaround was realized, which was mainly due to the increase in operating income and decrease in selling expenses for the current reporting period. |
| 归属于上市公司股东的净利润_年初至报告期末 | Net profit attributable to shareholders of listed companies_beginning to end of the current reporting period | 不适用 N/A | 与上年同期相比, 实现扭亏为盈, 主要系年初至报告期末营业收入增长、销售费用减少所致。 | Compared with the same period of the previous year, a turnaround was realized, which was mainly due to the increase in operating income and decrease in selling expenses from beginning to end of the current reporting period. |
| 归属于上市公司股东的扣除非经常性损益的净利润_本报告期 | Net profit attributable to shareholders of listed companies after deduction of non-recurring profits or losses_current reporting period | 不适用 N/A | 与上年同期相比, 实现扭亏为盈, 主要系本报告期营业收入增长、销售费用减少所致。 | Compared with the same period of the previous year, a turnaround was realized, which was mainly due to the increase in operating income and decrease in selling expenses for the current reporting period. |
| 归属于上市公司股东的扣除非经常性损益的净利润_年初至报告期末 | Net profit attributable to shareholders of listed companies after deduction of non-recurring profits or losses_beginning to end of the current reporting period | 不适用 N/A | 与上年同期相比, 实现扭亏为盈, 主要系年初至报告期末营业收入增长、销售费用减少所致。 | Compared with the same period of the previous year, a turnaround was realized, which was mainly due to the increase in operating income and decrease in selling expenses from beginning to end of the current reporting period. |
| 经营活动产生的现金流量净额_年初至报告期末 | Net cash flows from operating activities_beginning to end of the current reporting period | -116.70 | 主要系上年同期收回期初应收账款金额较高所致。 | Mainly due to a greater recovery of outstanding payments from beginning to end of the current reporting period. |

| | | | | |
|----------------|--|------------|---|---|
| 基本每股收益_本报告期 | Basic earnings per share_ current reporting period | 不适用 N/A | 与上年同期相比，实现扭亏为盈，主要系本报告期营业收入增长、销售费用减少所致。 | Compared with the same period of the previous year, a turnaround was realized, which was mainly due to the increase in operating income and decrease in selling expenses for the current reporting period. |
| 基本每股收益_年初至报告期末 | Basic earnings per share_ beginning to end of the current reporting period | 不适用 N/A | 与上年同期相比，实现扭亏为盈，主要系年初至报告期末营业收入增长、销售费用减少所致。 | Compared with the same period of the previous year, a turnaround was realized, which was mainly due to the increase in operating income and decrease in selling expenses from beginning to end of the current reporting period. |
| 稀释每股收益_本报告期 | Diluted earnings per share_ current reporting period | 不适用 N/A | 与上年同期相比，实现扭亏为盈，主要系本报告期营业收入增长、销售费用减少所致。 | Compared with the same period of the previous year, a turnaround was realized, which was mainly due to the increase in operating income and decrease in selling expenses for the current reporting period. |
| 稀释每股收益_年初至报告期末 | Diluted earnings per share_ beginning to end of the current reporting period | 不适用 N/A | 与上年同期相比，实现扭亏为盈，主要系年初至报告期末营业收入增长、销售费用减少所致。 | Compared with the same period of the previous year, a turnaround was realized, which was mainly due to the increase in operating income and decrease in selling expenses from beginning to end of the current reporting period. |

说明：

营业收入_本报告期变动原因分析如下：

2023年第三季度，公司营业收入为6.76亿元，与上年同期相比增长2.74亿元，较上年同期增长68.10%，主要系公司国内制剂产品销售收入较上年同期增加3.14亿元所致。

营业收入_年初至报告期末变动原因分析如下：

2023年前三季度，公司营业收入为19.06亿元，与上年同期相比增长6.69亿元，较上年同期增长54.07%。

Note:

The reasons for the changes in operating income_current reporting period are analyzed as follows:

In the third quarter of 2023, the Company generated operating income of RMB 676 million, a year-on-year increase of RMB 274 million representing a year-on-year growth of 68.10%, which was mainly due to the increase of RMB 314 million in the Company's domestic sales of preparation products compared to the same period of the previous year.

The reasons for the changes in operating income_beginning to end of the current reporting period are analyzed as follows:

For the first three quarters of 2023, the Company generated RMB 1.906 billion in revenue, a year-on-year increase of RMB 669 million representing a year-on-year growth of 54.07%.

营业收入分地区情况
Operating income by region

单位：万元
Unit: RMB 10,000

| 分地区 Region | 2023年前三季度 营业收入 Operating income for the first three quarters of 2023 | 2022年前三季度 营业收入 Operating income for the first three quarters of 2022 | 同期变动(%) Change over the period (%) |
|---|---|---|---------------------------------------|
| 国内-销售收入 Domestic - Sales revenue | 162,940.37 | 104,997.74 | 55.18 |
| 国际-销售收入 Overseas - Sales revenue | 17,609.24 | 5,217.98 | 237.47 |
| 国际-特许经营权服务收入 Overseas - Franchise service income | 10,017.48 | 13,473.23 | -25.65 |
| 营业收入合计 Total operating income | 190,567.09 | 123,688.95 | 54.07 |

(1) 公司国内销售收入较上年同期增长5.79亿元，主要系公司国内胰岛素制剂产品销量大幅增长所致。公司国内胰岛素制剂产品主要有基础(长效)胰岛素产品、餐时(速效)和预混胰岛素产品，其中基础(长效)胰岛素产品包括长秀霖®及长秀霖®预填充；餐时(速效)和预混胰岛素产品包括速秀霖®、速秀霖®25、速秀霖®预填充、锐秀霖®、锐秀霖®30和普秀霖®30。2023年前三季度，公司国内胰岛素制剂产品销量同期增长70.06%；公司基础(长效)胰岛素产品销售量同比增长36.24%；公司餐时(速效)和预混胰岛素产品得到迅速放量，销售量同比增长115.57%。

公司餐时(速效)和预混胰岛素产品销售量增长迅速，其销售量占国内胰岛素制剂产品销量的54.03%，对国内胰岛素制剂产品销量贡献不断增大。

(2) 公司国际销售订单增加，国际销售收入较上年同期增加1.24亿元，涨幅为237.47%。

(1) The Company's domestic sales revenue increased by RMB 579 million as compared with the same period of the previous year, mainly due to the substantial increase in sales of the Company's domestic insulin preparation products. The Company's domestic insulin preparation products mainly include basal (long-acting) insulin products, mealtime (fast-acting) and premixed insulin products, of which the basal (long-acting) insulin products include Basalin® and Basalin®Prefilled, and the mealtime (fast-acting) and premixed insulin products include Prandilin®, Prandilin®25, Prandilin®Prefilled, Raplin®, Raplin®30, and Similin®30. During the first three quarters of 2023, sales volume for the Company's domestic insulin preparation products increased by 70.06% compared to the same period. The sales volume of the Company's basal (long-acting) insulin products increased by 36.24% year-on-year. Furthermore, the Company's mealtime (fast-acting) and premixed insulin products received rapid volume release, with sales volume increasing by 115.57% year-on-year.

The sales volume of the Company's meal-time (fast-acting) and premixed insulin products grew rapidly, accounting for 54.03% of domestic insulin preparation product sales, and driving overall sales growth in this category.

(2) The Company experienced a significant increase in international sales orders, resulting in a substantial rise of RMB 124 million representing an increase of 237.47% in international sales revenue compared to the same period of the previous year.

股东信息

Shareholder Information



二、股东信息

II Shareholder Information

(一) 普通股股东总数和表决权恢复的优先股股东数量及前十名股东持股情况表

(I) Total number of common shareholders and the number of preferred shareholders with voting rights restored, and the top ten shareholders' shareholdings

单位：股
Unit: Share

| 报告期末普通股股东总数 | 79,170 | 报告期末表决权恢复的优先股股东总数(如有) | 无 | | |
|--|--|--|------------------------|----------------------------------|--|
| Total number of ordinary shareholders at the end of the current reporting period | | Total number of preferred shareholders with voting rights restored at the end of the current reporting period (if any) | None | | |
| 前10名股东持股情况 Shareholdings of top ten shareholders | | | | | |
| 股东名称 | 股东性质 | 持股数量 | 持股比例(%) | 持有有限售条件股份数量 | 质押、标记或冻结情况 |
| Shareholder name | Nature of shareholders | Number of shares held | Shareholding ratio (%) | Number of restricted shares held | Status of shares pledged, tagged or frozen |
| | | | | | 股份状态 Share status |
| 甘忠如 Zhongru Gan | 境内自然人 Domestic natural person | 177,135,207 | 31.32 | | 无 None |
| 北京旭特宏达科技有限公司 Beijing Xute Hongda Technology Co.,Ltd | 境内非国有法人 Domestic non-state-owned legal entity | 47,494,437 | 8.40 | | 无 None |
| 明华创新技术投资(香港)有限公司 MING HUA TECHNOLOGY INVESTMENT (HK) LIMITED | 境外法人 Overseas legal entity | 36,191,954 | 6.40 | 15,875,800 | 无 None |
| Vast Wintersweet Limited | 境外法人 Overseas legal entity | 17,643,473 | 3.12 | 5,777,913 | 无 None |
| 甘喜茹 Xiru Gan | 境内自然人 Domestic natural person | 6,223,276 | 1.10 | | 无 None |
| 香港中央结算有限公司 Hong Kong Securities Clearing Company Limited | 其他 Other | 5,602,674 | 0.99 | | 无 None |
| JPMORGAN CHASE BANK, NATIONAL ASSOCIATION | 境外法人 Overseas legal entity | 5,509,000 | 0.97 | | 无 None |
| Hillhouse G&L Holdings (HK) Limited | 境外法人 Overseas legal entity | 4,357,832 | 0.77 | 4,296,032 | 无 None |
| STRONG LINK INTERNATIONAL LIMITED | 国有法人 State-owned legal entity | 4,256,033 | 0.75 | 4,256,033 | 无 None |
| 中国银行股份有限公司－招商国证生物医药指数分级证券投资基金 Bank of China Limited - China Merchants CSI Biomedical Index Split-level Securities Investment Fund | 其他 Other | 3,629,900 | 0.64 | | 无 None |

单位：股
Unit: Share

| 前10名无限售条件股东持股情况 Shareholdings of the top ten shareholders with unlimited trading conditions | | | |
|---|--|--|-------------|
| 股东名称 Shareholder name | 持有无限售条件流通股的 数量 Number of unlimited shares outstanding | 股份种类及数量 Category and number of shares | |
| | | 股份种类 Category | 数量 Numbe |
| 甘忠如 Zhongru Gan | 177,135,207 | 人民币普通股 RMB ordinary shares | 177,135,207 |
| 北京旭特宏达科技有限公司 Beijing Xute Hongda Technology Co.,Ltd | 47,494,437 | 人民币普通股 RMB ordinary shares | 47,494,437 |
| 明华创新技术投资(香港)有限公司 MING HUA TECHNOLOGY INVESTMENT (HK) LIMITED | 20,316,154 | 人民币普通股 RMB ordinary shares | 20,316,154 |
| Vast Wintersweet Limited | 11,865,560 | 人民币普通股 RMB ordinary shares | 11,865,560 |
| 甘喜茹 Xiru Gan | 6,223,276 | 人民币普通股 RMB ordinary shares | 6,223,276 |
| 香港中央结算有限公司 Hong Kong Securities Clearing Company Limited | 5,602,674 | 人民币普通股 RMB ordinary shares | 5,602,674 |
| JPMORGAN CHASE BANK, NATIONAL ASSOCIATION | 5,509,000 | 人民币普通股 RMB ordinary shares | 5,509,000 |
| 中国银行股份有限公司－招商国证生物医药指数分级证 券投资基金 Bank of China Limited - China Merchants CSI Biomedical Index Split-level Securities Investment Fund | 3,629,900 | 人民币普通股 RMB ordinary shares | 3,629,900 |
| 招商银行股份有限公司－南方阿尔法混合型证券投资基 金 China Merchants Bank Corporation - Southern Alpha Mixed Securities Investment Fund | 3,501,463 | 人民币普通股 RMB ordinary shares | 3,501,463 |
| 中国农业银行股份有限公司－鹏华医药科技股票型证券 投资基金 Agricultural Bank of China Limited - Penghua Pharmaceutical Technology Equity Fund | 2,914,600 | 人民币普通股 RMB ordinary shares | 2,914,600 |
| 上述股东关联关系或一致行动的说明 Explanation of the above shareholders' affiliation or concerted action | | 公司控股股东、实际控制人甘忠如持有旭特宏达65.02%的股权；甘喜茹为 甘忠如胞妹。除以上情况外，其他股东之间不存在关联关系或一致行动。 Zhongru Gan, the controlling shareholder and actual controller of the Company, holds 65.02% of the shares of Beijing Xute Hongda Technology Co.,Ltd; Xiru Gan is the sibling of Zhongru Gan. Apart from the above, there is no affiliation or concerted action among other shareholders. | |
| 前10名股东及前10名无限售股东参与融资融券及转融通 业务情况说明(如有) Explanation on the participation of the top ten shareholders and the top ten unlimited shareholders in the margin financing and securities lending and refinancing business (if any) | | 无 None | |

季度财务报表

Quarterly Financial Statements



三、季度财务报表

III Quarterly Financial Statements

(一) 财务报表

(I) Financial statements

合并资产负债表
Consolidated statement of financial position

2023年9月30日
September 30, 2023

编制单位:甘李药业股份有限公司
Prepared by: Gan & Lee Pharmaceuticals.

单位:元 币种:人民币 审计类型:未经审计
Unit: RMB Audit type: Unaudited

| 项目 | Item | 2023年9月30日 September 30, 2023 | 2022年12月31日 December 31, 2022 |
|---------------|--|----------------------------------|----------------------------------|
| 流动资产: | Current Assets: | | |
| 货币资金 | Cash and Cash equivalents | 2,093,406,319.02 | 2,890,266,792.18 |
| 交易性金融资产 | Financial assets held for trading | 2,077,608,224.29 | 1,635,949,901.34 |
| 应收账款 | Accounts receivable | 398,288,006.98 | 176,251,160.43 |
| 应收款项融资 | Financing receivables | 17,900,528.40 | 13,316,425.56 |
| 预付款项 | Prepayments | 36,306,664.98 | 45,978,647.53 |
| 其他应收款 | Other receivables | 3,859,363.88 | 5,888,971.68 |
| 存货 | Inventories | 858,848,392.87 | 648,645,609.14 |
| 一年内到期的非流动资产 | Non-current assets due within one year | | 201,358,630.13 |
| 其他流动资产 | Other current assets | 1,963,899.71 | 46,480,151.30 |
| 流动资产合计 | Total current assets | 5,488,181,400.13 | 5,664,136,289.29 |
| 非流动资产: | Non-current Assets: | | |
| 债权投资 | Debt investment | 302,166,666.67 | |
| 其他非流动金融资产 | Other non-current financial assets | 30,000,000.00 | 30,000,000.00 |
| 固定资产 | Fixed assets | 1,813,532,086.73 | 1,646,528,285.07 |
| 在建工程 | Construction in progress | 1,894,127,467.15 | 2,002,728,242.12 |
| 使用权资产 | Right-of-use assets | 9,160,983.53 | 12,080,372.03 |
| 无形资产 | Intangible assets | 280,506,605.44 | 293,480,707.13 |
| 开发支出 | Development expenditures | 795,570,714.94 | 732,562,121.88 |
| 长期待摊费用 | Long-term deferred expenses | 9,312,158.66 | 10,632,701.96 |
| 递延所得税资产 | Deferred tax assets | 109,451,926.06 | 138,250,375.69 |
| 其他非流动资产 | Other non-current assets | 93,027,565.30 | 76,513,284.89 |
| 非流动资产合计 | Total non-current assets | 5,336,856,174.48 | 4,942,776,090.77 |
| 资产总计 | Total assets | 10,825,037,574.61 | 10,606,912,380.06 |

合并资产负债表 (续)
Consolidated statement of financial position (Continued)

| 项目 | Item | 2023年9月30日 September 30, 2023 | 2022年12月31日 December 31, 2022 |
|--------------------------|---|----------------------------------|----------------------------------|
| 流动负债: | Current Liabilities | | |
| 应付账款 | Accounts payable | 89,744,391.36 | 44,692,994.55 |
| 预收款项 | Receipts in advance | | 603,555.70 |
| 合同负债 | Contract liabilities | 47,599,346.55 | 68,125,067.69 |
| 应付职工薪酬 | Payroll and employee benefits payable | 142,067,160.12 | 142,022,574.85 |
| 应交税费 | Taxes payable | 22,102,737.34 | 14,413,032.33 |
| 其他应付款 | Other payables | 400,708,144.18 | 534,680,233.19 |
| 一年内到期的非流动负债 | Non-current liabilities due within one year | 15,275,760.16 | 7,563,363.97 |
| 其他流动负债 | Other current liabilities | 158,356.62 | 936,179.18 |
| 流动负债合计 | Total current liabilities | 717,655,896.33 | 813,037,001.46 |
| 非流动负债: | Non-current Liabilities: | | |
| 租赁负债 | Lease liabilities | 8,180,032.99 | 8,327,140.36 |
| 长期应付款 | Long-term payable | 14,614,041.61 | 12,274,100.29 |
| 递延收益 | Deferred income | 182,698,431.05 | 187,634,504.08 |
| 递延所得税负债 | Deferred tax liabilities | 11,445,496.57 | |
| 非流动负债合计 | Total non-current liabilities | 216,938,002.22 | 208,235,744.73 |
| 负债合计 | Total liabilities | 934,593,898.55 | 1,021,272,746.19 |
| 所有者权益(或股东权益): | Owners equity (or shareholders' equity): | | |
| 实收资本(或股本) | Paid-in capital (or share capital) | 565,653,200.00 | 565,653,200.00 |
| 资本公积 | Capital reserve | 2,600,461,124.09 | 2,563,002,386.27 |
| 减: 库存股 | Less: Treasury share | 71,364,020.00 | 71,364,020.00 |
| 其他综合收益 | Other comprehensive income | 4,311,585.79 | 3,442,128.87 |
| 盈余公积 | Surplus reserve | 291,531,843.96 | 291,531,843.96 |
| 未分配利润 | Retained earnings | 6,500,012,491.06 | 6,233,536,610.40 |
| 归属于母公司所有者权益(或股东权益)合计 | Total owner's equity (or shareholders' equity) attributable to the parent company | 9,890,606,224.90 | 9,585,802,149.50 |
| 少数股东权益 | Non-controlling interests | -162,548.84 | -162,515.63 |
| 所有者权益(或股东权益)合计 | Total owners' equity (or shareholders' equity) | 9,890,443,676.06 | 9,585,639,633.87 |
| 负债和所有者权益(或股东权益)总计 | Total Liabilities and shareholders' equity | 10,825,037,574.61 | 10,606,912,380.06 |

| | | | | | |
|-----------------------|-------------|-------------------|-----------|--------------------------------|---------|
| 公司负责人: | 甘忠如 | 主管会计工作负责人: | 孙程 | 会计机构负责人: | 周丽 |
| Legal Representative: | Zhongru Gan | Chief Accountant: | Cheng Sun | Head of Accounting Department: | Li Zhou |

合并利润表

Consolidated Income Statement

2023年1—9月
Jan to Sept, 2023

编制单位:甘李药业股份有限公司
Prepared by: Gan & Lee Pharmaceuticals.

单位:元 币种:人民币 审计类型:未经审计
Unit: RMB Audit type: Unaudited

| 项目 | Item | 2023年前三季度(1-9月) First three quarters of 2023 (Jan.-Sept.) | 2022年前三季度(1-9月) First three quarters of 2022 (Jan.-Sept.) |
|-----------------------|--|---|---|
| 一、营业总收入 | I. Total Revenue | 1,905,670,877.67 | 1,236,889,504.93 |
| 其中:营业收入 | Of which: Operating income | 1,905,670,877.67 | 1,236,889,504.93 |
| 二、营业总成本 | II. Total operating costs | 1,645,843,381.45 | 1,617,968,377.67 |
| 其中:营业成本 | Of which: Operating costs | 481,189,719.14 | 270,759,943.28 |
| 税金及附加 | Taxes and surcharges | 17,933,843.14 | 16,262,299.31 |
| 销售费用 | Selling expenses | 703,633,555.05 | 829,616,154.57 |
| 管理费用 | General and administrative expenses | 141,626,147.56 | 179,934,406.68 |
| 研发费用 | R&D expenses | 369,945,734.16 | 393,203,255.33 |
| 财务费用 | Financial expenses | -68,485,617.60 | -71,807,681.50 |
| 加:其他收益 | Add: Other income | 13,936,831.47 | 34,406,183.78 |
| 投资收益(损失以“—”号填列) | Investment income or loss (loss is indicated with "-") | 59,839,944.90 | 91,350,577.64 |
| 公允价值变动收益(损失以“—”号填列) | Gain or loss on the changes in fair value (loss is indicated with "-") | -17,576,525.82 | -137,237,269.09 |
| 信用减值损失(损失以“—”号填列) | Credit impairment losses (loss is indicated with "-") | 4,492,847.21 | -15,443,379.89 |
| 资产减值损失(损失以“—”号填列) | Assets impairment losses (loss is indicated with "-") | -3,352,763.40 | -20,292,362.53 |
| 资产处置收益(损失以“—”号填列) | Gain or loss from disposal of assets (loss is indicated with "-") | 45,822.47 | -1,521.66 |
| 三、营业利润(亏损以“—”号填列) | III. Operating Profit (loss is indicated with "-") | 317,213,653.05 | -428,296,644.49 |
| 加:营业外收入 | Add: Non-operating income | 2,931,333.37 | 2,268,895.53 |
| 减:营业外支出 | Less: Non-operating expenses | 9,123,853.22 | 6,877,433.59 |
| 四、利润总额(亏损总额以“—”号填列) | IV. Profit before tax (loss is indicated with "-") | 311,021,133.20 | -432,905,182.55 |
| 减:所得税费用 | Less: Income tax expense | 44,545,285.75 | -19,099,237.18 |
| 五、净利润(净亏损以“—”号填列) | V. Net Profit (loss is indicated with "-") | 266,475,847.45 | -413,805,945.37 |
| (一)按经营持续性分类 | (I) Categorized by operation continuity | | |
| 1.持续经营净利润(净亏损以“—”号填列) | 1. Net profit from continuing operations (loss is indicated with "-") | 266,475,847.45 | -413,805,945.37 |

合并利润表 (续)
Consolidated Income Statement (Continued)

| 项目 | Item | 2023年前三季度(1-9月) First three quarters of 2023 (Jan.-Sept.) | 2022年前三季度(1-9月) First three quarters of 2022 (Jan.-Sept.) |
|-----------------------------|--|---|---|
| (二) 按所有权归属分类 | (II) Categorized by ownership | | |
| 1. 归属于母公司股东的净利润(净亏损以“-”号填列) | 1. Net profit attributable to owners of the parent (net loss is indicated with "-") | 266,475,880.66 | -413,805,916.81 |
| 2. 少数股东损益(净亏损以“-”号填列) | 2. Net profit attributable to non-controlling interests (net loss is indicated with "-") | -33.21 | -28.56 |
| 六、其他综合收益的税后净额 | VI. Other comprehensive income net of tax | 869,456.92 | 8,574,424.61 |
| (一) 归属母公司所有者的其他综合收益的税后净额 | (I) Other comprehensive income net of tax attributable to owners of the parent | 869,456.92 | 8,574,424.61 |
| 1. 不能重分类进损益的其他综合收益 | 1. Other comprehensive income cannot be reclassified to profit or loss | | |
| 2. 将重分类进损益的其他综合收益 | 2. Other comprehensive income to be reclassified to profit or loss | 869,456.92 | 8,574,424.61 |
| (1) 外币财务报表折算差额 | (1) Exchange differences on translation of foreign currency financial statements | 869,456.92 | 8,574,424.61 |
| (二) 归属于少数股东的其他综合收益的税后净额 | (II) Other comprehensive income net of tax attributable to non-controlling interests | | |
| 七、综合收益总额 | VII. Total Comprehensive Income | 267,345,304.37 | -405,231,520.76 |
| (一) 归属于母公司所有者的综合收益总额 | (I) Total comprehensive income attributable to owners of the parent | 267,345,337.58 | -405,231,492.20 |
| (二) 归属于少数股东的综合收益总额 | (II) Total comprehensive income attributable to non-controlling interests | -33.21 | -28.56 |
| 八、每股收益： | VIII. Earnings Per Share: | | |
| (一) 基本每股收益(元/股) | (I) Basic earnings per share (RMB per share) | 0.47 | -0.74 |
| (二) 稀释每股收益(元/股) | (II) Diluted earnings per share (RMB per share) | 0.47 | -0.74 |

本期发生同一控制下企业合并的，被合并方在合并前实现的净利润为：0元，上期被合并方实现的净利润为：0元。

As for a business combination under the same control in the current period, the net profit generated by the merged party before the combination was: RMB 0, and that generated during the previous period was: RMB 0.

| | | | | | |
|-----------------------|-------------|-------------------|-----------|--------------------------------|---------|
| 公司负责人： | 甘忠如 | 主管会计工作负责人： | 孙程 | 会计机构负责人： | 周丽 |
| Legal Representative: | Zhongru Gan | Chief Accountant: | Cheng Sun | Head of Accounting Department: | Li Zhou |

合并现金流量表

Consolidated Statement of Cash Flows

2023年1—9月
Jan to Sept, 2023

编制单位:甘李药业股份有限公司
Prepared by: Gan & Lee Pharmaceuticals.

单位:元 币种:人民币 审计类型:未经审计
Unit: RMB Audit type: Unaudited

| 项目 | Item | 2023年前三季度(1-9月) First three quarters of 2023 (Jan.-Sept.) | 2022年前三季度(1-9月) First three quarters of 2022 (Jan.-Sept.) |
|---------------------------|---|---|---|
| 一、经营活动产生的现金流量: | | | |
| 销售商品、提供劳务收到的现金 | Cash receipts from the sale of goods and the rendering of services | 1,694,545,146.87 | 2,103,848,337.34 |
| 收到的税费返还 | Tax refunds received | 60,108,069.51 | 98,655,567.68 |
| 收到其他与经营活动有关的现金 | Cash received relating to other operating activities | 18,298,113.92 | 89,918,855.54 |
| 经营活动现金流入小计 | Sub-total of cash inflows from operating activities | 1,772,951,330.30 | 2,292,422,760.56 |
| 购买商品、接受劳务支付的现金 | Cash paid for purchase of goods and services | 583,746,062.18 | 368,508,451.85 |
| 支付给职工及为职工支付的现金 | Cash paid to and on behalf of employees | 560,703,892.71 | 490,258,522.78 |
| 支付的各项税费 | Cash paid for taxes | 18,810,397.10 | 205,217,687.50 |
| 支付其他与经营活动有关的现金 | Cash paid relating to other operating activities | 686,647,237.11 | 767,642,090.85 |
| 经营活动现金流出小计 | Sub-total of cash outflows from operating activities | 1,849,907,589.10 | 1,831,626,752.98 |
| 经营活动产生的现金流量净额 | Net cash flows from operating activities | -76,956,258.80 | 460,796,007.58 |
| 二、投资活动产生的现金流量: | | | |
| 收回投资收到的现金 | Cash received from recovery of investments | 5,624,282,000.44 | 3,526,000,000.00 |
| 取得投资收益收到的现金 | Cash receipts from investment income | 275,784,951.06 | 105,192,274.78 |
| 处置固定资产、无形资产和其他长期资产收回的现金净额 | Net proceeds from disposal of fixed assets, intangible assets, and other long-term assets | 190,000.00 | |
| 收到其他与投资活动有关的现金 | Other cash received related to investing activities | 14,409,970.30 | |
| 投资活动现金流入小计 | Sub-total of cash inflows from investing activities | 5,914,666,921.80 | 3,631,192,274.78 |
| 购建固定资产、无形资产和其他长期资产支付的现金 | Purchase of fixed assets, intangible assets, and other non-current assets | 346,811,677.15 | 712,077,789.23 |
| 投资支付的现金 | Cash paid for investments | 5,448,209,000.03 | 3,505,496,000.00 |
| 支付其他与投资活动有关的现金 | Cash paid relating to other investing activities | 46,103,532.84 | 25,312,349.42 |
| 投资活动现金流出小计 | Sub-total of cash outflows from investing activities | 5,841,124,210.02 | 4,242,886,138.65 |
| 投资活动产生的现金流量净额 | Net cash flows from investing activities | 73,542,711.78 | -611,693,863.87 |

合并现金流量表 (续)
Consolidated Statement of Cash Flows (Continued)

| 项目 | Item | 2023年前三季度 (1-9月) First three quarters of 2023 (Jan.-Sept.) | 2022年前三季度 (1-9月) First three quarters of 2022 (Jan.-Sept.) |
|---------------------------|---|--|--|
| 三、筹资活动产生的现金流量： | III. Cash Flows from Financing Activities: | | |
| 吸收投资收到的现金 | Cash received from investments | | |
| 筹资活动现金流入小计 | Subtotal of cash inflows from financing activities | | |
| 分配股利、利润或偿付利息支付的现金 | Cash payments for distribution of dividends, profit and interest expenses | | 168,462,000.00 |
| 支付其他与筹资活动有关的现金 | Cash payments relating to other financing activities | 3,503,968.02 | 851,551.25 |
| 筹资活动现金流出小计 | Sub-total of cash outflows from financing activities | 3,503,968.02 | 169,313,551.25 |
| 筹资活动产生的现金流量净额 | Net cash flow from financing activities | -3,503,968.02 | -169,313,551.25 |
| 四、汇率变动对现金及现金等价物的影响 | IV. Effect of exchange rate changes on cash and cash equivalents | 3,097,103.59 | 9,674,073.60 |
| 五、现金及现金等价物净增加额 | V. Net increase in cash and cash equivalents | -3,820,411.45 | -310,537,333.94 |
| 加：期初现金及现金等价物余额 | Add: Cash and cash equivalents at beginning of period | 397,328,882.98 | 639,768,344.07 |
| 六、期末现金及现金等价物余额 | VI. Cash and cash equivalents at end of period | 393,508,471.53 | 329,231,010.13 |

| | | | | | |
|-----------------------|-------------|-------------------|-----------|--------------------------------|---------|
| 公司负责人： | 甘忠如 | 主管会计工作负责人： | 孙程 | 会计机构负责人： | 周丽 |
| Legal Representative: | Zhongru Gan | Chief Accountant: | Cheng Sun | Head of Accounting Department: | Li Zhou |

2023年起首次执行新会计准则或准则解释等涉及调整首次执行当年年初的财务报表

调整当年年初财务报表的原因说明

2022年，财政部发布了《企业会计准则解释第16号》(财会〔2022〕31号，以下简称“解释16号”)，其中“关于单项交易产生的资产和负债相关的递延所得税不适用初始确认豁免的会计处理”规定，自2023年1月1日起施行。

公司自2023年1月1日起施行解释16号，并根据准则解释要求，对因适用该解释的单项交易而确认的租赁负债和使用权资产，产生的应纳税暂时性差异和可抵扣暂时性差异，按照该解释和《企业会计准则第18号——所得税》的规定，将累计影响数调整财务报表列报最早期间的期初留存收益及其他相关财务报表项目。

First-time implementation of new accounting standards or interpretations, etc. from 2023 onwards involves adjustments to the financial statements at beginning of the year of initial implementation

Statement of reasons for adjustments to the financial statements as at beginning of the year

In 2022, the Ministry of Finance issued "Interpretation No.16 of the Accounting Standards for Business Enterprises" (Accounting [2022] No.31, hereinafter referred to as "Interpretation No.16"), which stipulates that "Accounting for deferred taxes related to assets and liabilities arising from individual transactions to which the initial recognition exemption does not apply", which will take effect on 1 January 2023, is not applicable to deferred taxes related to assets and liabilities that arise from individual transactions.

The Company adopted "Interpretation No.16" on January 1, 2023, and in accordance with the cumulative effect of "Interpretation No.16" and "Accounting Standard for Business Enterprises No.18, Income Taxes", the Company is required to adjust the cumulative effect of taxable temporary differences and deductible temporary differences arising from lease liabilities and right-of-use assets recognized as a result of a single transaction for which the Interpretation applies to, against opening retained earnings and other relevant financial statement items in the earliest period for which the financial statements are presented.

合并资产负债表

Consolidated statement of financial position

单位：元 币种：人民币
Unit: RMB

| 项目 | Item | 2022年12月31日 December 31, 2022 | 2023年1月1日 January 1, 2023 | 调整数 Adjustments |
|---------------|---|----------------------------------|------------------------------|--------------------|
| 流动资产： | Current Assets: | | | |
| 货币资金 | Cash and Cash equivalents | 2,890,266,792.18 | 2,890,266,792.18 | |
| 交易性金融资产 | Financial assets held for trading | 1,635,949,901.34 | 1,635,949,901.34 | |
| 应收账款 | Accounts receivable | 176,251,160.43 | 176,251,160.43 | |
| 应收款项融资 | Receivables financing | 13,316,425.56 | 13,316,425.56 | |
| 预付款项 | Prepayments | 45,978,647.53 | 45,978,647.53 | |
| 其他应收款 | Other receivables | 5,888,971.68 | 5,888,971.68 | |
| 存货 | Inventories | 648,645,609.14 | 648,645,609.14 | |
| 一年内到期的非流动资产 | Non-current assets due within one year | 201,358,630.13 | 201,358,630.13 | |
| 其他流动资产 | Other current assets | 46,480,151.30 | 46,480,151.30 | |
| 流动资产合计 | Total current assets | 5,664,136,289.29 | 5,664,136,289.29 | |
| 非流动资产： | Non-current Assets: | | | |
| 其他非流动金融资产 | Other non-current financial assets | 30,000,000.00 | 30,000,000.00 | |
| 固定资产 | Fixed assets | 1,646,528,285.07 | 1,646,528,285.07 | |
| 在建工程 | Construction in progress | 2,002,728,242.12 | 2,002,728,242.12 | |
| 使用权资产 | Right-of-use assets | 12,080,372.03 | 12,080,372.03 | |
| 无形资产 | Intangible assets | 293,480,707.13 | 293,480,707.13 | |
| 开发支出 | Development expenditures | 732,562,121.88 | 732,562,121.88 | |
| 长期待摊费用 | Long-term deferred expenses | 10,632,701.96 | 10,632,701.96 | |
| 递延所得税资产 | Deferred tax assets | 138,250,375.69 | 138,250,375.69 | |
| 其他非流动资产 | Other non-current assets | 76,513,284.89 | 76,513,284.89 | |
| 非流动资产合计 | Total non-current assets | 4,942,776,090.77 | 4,942,776,090.77 | |
| 资产总计 | Total assets | 10,606,912,380.06 | 10,606,912,380.06 | |
| 流动负债： | Current liabilities: | | | |
| 应付账款 | Accounts payable | 44,692,994.55 | 44,692,994.55 | |
| 预收款项 | Receipts in advance | 603,555.70 | 603,555.70 | |
| 合同负债 | Contract liabilities | 68,125,067.69 | 68,125,067.69 | |
| 应付职工薪酬 | Payroll and employee benefits payable | 142,022,574.85 | 142,022,574.85 | |
| 应交税费 | Taxes payable | 14,413,032.33 | 14,413,032.33 | |
| 其他应付款 | Other payables | 534,680,233.19 | 534,680,233.19 | |
| 一年内到期的非流动负债 | Non-current liabilities due within one year | 7,563,363.97 | 7,563,363.97 | |

合并资产负债表 (续)
Consolidated statement of financial position (Continued)

| 项目 | Item | 2022年12月31日 December 31, 2022 | 2023年1月1日 January 1, 2023 | 调整数 Adjustments |
|-------------------------------|---|----------------------------------|------------------------------|--------------------|
| 其他流动负债 | Other current liabilities | 936,179.18 | 936,179.18 | |
| 流动负债合计 | Total current liabilities | 813,037,001.46 | 813,037,001.46 | |
| 非流动负债: | Non-current Liabilities: | | | |
| 租赁负债 | Lease liabilities | 8,327,140.36 | 8,327,140.36 | |
| 长期应付款 | Long-term payable | 12,274,100.29 | 12,274,100.29 | |
| 递延收益 | Deferred income | 187,634,504.08 | 187,634,504.08 | |
| 递延所得税负债 | Deferred tax liabilities | | | |
| 非流动负债合计 | Total non-current liabilities | 208,235,744.73 | 208,235,744.73 | |
| 负债合计 | Total liabilities | 1,021,272,746.19 | 1,021,272,746.19 | |
| 所有者权益(或股东权益): | Owners (or Shareholders') equity: | | | |
| 实收资本(或股本) | Paid-in capital (or share capital) | 565,653,200.00 | 565,653,200.00 | |
| 资本公积 | Capital reserve | 2,563,002,386.27 | 2,563,002,386.27 | |
| 减: 库存股 | Less: Treasury stocks | 71,364,020.00 | 71,364,020.00 | |
| 其他综合收益 | Other comprehensive income | 3,442,128.87 | 3,442,128.87 | |
| 盈余公积 | Surplus reserve | 291,531,843.96 | 291,531,843.96 | |
| 未分配利润 | Retained earnings | 6,233,536,610.40 | 6,233,536,610.40 | |
| 归属于母公司所有者权益 (或股东权益) 合计 | Total owner's equity (or shareholders' equity) attributable to the parent company | 9,585,802,149.50 | 9,585,802,149.50 | |
| 少数股东权益 | Non-controlling interests | -162,515.63 | -162,515.63 | |
| 所有者权益(或股东权益) 合计 | Total owners' equity (or shareholders' equity) | 9,585,639,633.87 | 9,585,639,633.87 | |
| 负债和所有者权益(或股东权益) 总计 | Total liabilities and shareholders' equity | 10,606,912,380.06 | 10,606,912,380.06 | |

说明：

对2023年1月1日递延所得税资产的影响为：未经抵销的递延所得税资产增加1,588,573.11元、递延所得税资产和负债期末互抵金额增加1,588,573.11元、抵销后净额列示的递延所得税资产增加0.00元。

对2023年1月1日递延所得税负债的影响为：未经抵销的递延所得税负债增加1,588,573.11元、递延所得税资产和负债期末互抵金额增加1,588,573.11元、抵销后净额列示的递延所得税负债增加0.00元。

特此公告

Notes:

The effect on deferred tax assets at January 1, 2023 was: Increase of RMB 1,588,573.11 in unoffset deferred tax assets, increase of RMB 1,588,573.11 in the amount of offsetting deferred tax assets and liabilities at the end of the current period, and increase of RMB 0.00 in deferred tax assets presented net of offsets.

The effect on deferred tax liabilities at January 1, 2023 was: Increase of RMB 1,588,573.11 in unoffset deferred tax liabilities, increase of RMB 1,588,573.11 in the amount of offsetting deferred tax assets and liabilities at the end of the period, and increase of RMB 0.00 in deferred tax liabilities presented net of offsets.

Hereby notify the above notice.

甘李药业股份有限公司董事会
Gan & Lee Pharmaceuticals. Board of Directors

2023年10月27日
October 27, 2023



SCIENCE & EXCELLENCE

甘李药业股份有限公司

地址：北京市通州区潮县镇南凤西一路8号

网址：<http://www.ganlee.com>

电话：+86 010-80593699

邮编：101109